Romosozumab for the treatment of osteoporosis

References

• Kanis JA, Melton III J, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–1141.
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–795.
   PubMed Web of Science ®Google Scholar
• Holanda NCP, Carvalho NC, Egito K, et al. Osteoporose: epidemiologia, Classificação e Diagnóstico. In: F. Bandeira, Editors. Endocrinologia e Diabetes. Medbook: Rio de Janeiro-RJ, Brazil; 2015. 457–473.
   Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57.
   PubMed Web of Science ®Google Scholar
• Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–1768.
   PubMed Web of Science ®Google Scholar
• Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29:2520–2526.
   PubMed Web of Science ®Google Scholar
• Cianferotti L, D’Asta F, Brandi ML. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2013;5:127–139.
   PubMedGoogle Scholar
• Recker R, Lappe J, Davies KM, et al. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res. 2004;19:1628–1633.
   PubMed Web of Science ®Google Scholar
• Macedo JM, Macedo CR, Elkis H, et al. Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis. J Clin Pharm Ther. 1998;23:345–352.
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905–916.
   PubMed Web of Science ®Google Scholar
• Pazianas M. Anabolic effects of PTH and the ‘anabolic window’. Trends Endocrinol Metab. 2015;26:111–113.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Cosman F, De Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359–2381.
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267–2294.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29:1929–1937.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013;57:423–428.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822.
   PubMed Web of Science ®Google Scholar
• Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999;9:461–468.
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–1352.
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016;22:1–42.
   PubMed Web of Science ®Google Scholar
• Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord. 2006;7:113–121.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441.
   PubMed Web of Science ®Google Scholar
• McClung MR. Emerging therapies for osteoporosis. Endocrinol Metab (Seoul). 2015;30:429–435.
   PubMedGoogle Scholar
• Geusens P. New insights into treatment of osteoporosis in postmenopausal women. RMD Open. 2015;1:e000051.
   PubMed Web of Science ®Google Scholar
• Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–192.
   PubMed Web of Science ®Google Scholar
• Hikita A, Iimura T, Oshima Y, et al. Analyses of bone modeling and remodeling using in vitro reconstitution system with two-photon microscopy. Bone. 2015;76:5–17.
   PubMed Web of Science ®Google Scholar
• Seeman E. Bone modeling and remodeling. Crit Rev Eukaryot Gene Expr. 2009;19:219–233.
   PubMed Web of Science ®Google Scholar
• Wei W, Zeve D, Suh JM, et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol. 2011;31:4706–4719.
   PubMed Web of Science ®Google Scholar
• Rossini M, Gatti D, Adami S. Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93:121–132.
   PubMed Web of Science ®Google Scholar
• Spencer GJ, Utting JC, Etheridge SL, et al. WNT signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006;119:1283–1296.
   PubMed Web of Science ®Google Scholar
• Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical WNT signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751–764.
   PubMed Web of Science ®Google Scholar
• Costa AG, Bilezikian JP. Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep. 2012;10:64–72.
   PubMed Web of Science ®Google Scholar
• Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537–543.
   PubMed Web of Science ®Google Scholar
• Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577–589.
   PubMed Web of Science ®Google Scholar
• Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91–97.
   PubMed Web of Science ®Google Scholar
• Stein SA, Witkop C, Hill S, et al. Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology. 1983;33:267–277.
   PubMed Web of Science ®Google Scholar
• Van Buchem FS, Hadders HN, Ubbens R. An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol. 1955;44:109–120.
   PubMed Web of Science ®Google Scholar
• Truswell AS. Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg’s disease. J Bone Joint Surg Br. 1958;40-b:209–218.
   PubMedGoogle Scholar
• Gardner JC, Van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005;90:6392–6395.
   PubMed Web of Science ®Google Scholar
• Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab. 2003;88:5778–5783.
   PubMed Web of Science ®Google Scholar
• Van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26:2804–2811.
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860–869.
   PubMed Web of Science ®Google Scholar
• Li C, Ominsky MS, Tan HL, et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone. 2011;49:1178–1185.
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578–588.
   PubMed Web of Science ®Google Scholar
• Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25:2647–2656.
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152:3312–3322.
   PubMed Web of Science ®Google Scholar
• Marenzana M, Greenslade K, Eddleston A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum. 2011;63:2385–2395.
   PubMed Web of Science ®Google Scholar
• Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009;24:1662–1671.
   PubMed Web of Science ®Google Scholar
• Tian X, Jee WS, Li X, et al. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011;48:197–201.
   PubMed Web of Science ®Google Scholar
• Agholme F, Li X, Isaksson H, et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010;25:2412–2418.
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25:948–959.
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Boyd SK, Varela A, et al. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2016;32:1–14.
   Web of Science ®Google Scholar
• Babcook JS, Leslie KB, Olsen OA, et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A. 1996;93:7843–7848.
   PubMed Web of Science ®Google Scholar
• Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of WNT-mediated bone formation. J Biol Chem. 2009;284:10890–10900.
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19–26.
   PubMed Web of Science ®Google Scholar
• Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54:168–178.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412–420.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Krege JH, Marin F, et al. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int. 2016;27:2395–2410.
   PubMed Web of Science ®Google Scholar
• Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148–158.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–1543.
   PubMed Web of Science ®Google Scholar
• Graeff C, Campbell GM, Pena J, et al. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone. 2015;81:364–369.
   PubMed Web of Science ®Google Scholar
• Genant HK, Engelke K, Bolognese MA, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2016;32:1–7-181–7.
   Web of Science ®Google Scholar
• Kanis JA, Oden A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23:2239–2256.
   PubMed Web of Science ®Google Scholar
• Zerbini CA, Szejnfeld VL, Abergaria BH, et al. Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos. 2015;10:224.
   PubMed Web of Science ®Google Scholar
• Johnell O, Borgstrom F, Jonsson B, et al. Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int. 2007;18:333–337.
   PubMed Web of Science ®Google Scholar
• UCB and Amgen announce positive topline results from phase 3 study evaluating romosozumab in men with osteoporosis. 2016. Available at: http://eu.vocuspr.com/ViewAttachment.aspx?EID=hciRJLtApyzzYk8gYkD3EaV00Ecvcm3r0C6TANbEEn0%3d [Last accessed 14 September 2016];
   Google Scholar
• Langdahl B, Libanati C, Crittenden DB, et al. Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy: results of the phase 3 open-label structure study, in ENDO 2016. Boston, MA; 2016.
   Google Scholar
• Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.
   PubMed Web of Science ®Google Scholar
• Nusse R, Varmus H. Three decades of WNTs: a personal perspective on how a scientific field developed. Embo J. 2012;31:2670–2684.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312–321.
   PubMed Web of Science ®Google Scholar
• Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429–2437.
   PubMed Web of Science ®Google Scholar
• Elraiyah T, Gionfriddo MR, Murad MH. Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide. J Clin Epidemiol. 2015;68:698–702.
   PubMed Web of Science ®Google Scholar
• Chouinard L, Felx M, Mellal N, et al. Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Pharmacol. 2016;81:212–222.
   PubMed Web of Science ®Google Scholar